EnBiotix

EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections

EnBiotix is a product-focused bioengineering company commercializing anti-infective inventions of EnBiotix co-founder and SAB Chair Professor James J. Collins. Through breakthrough systems and synthetic biology platforms, EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections. These approaches have developed a robust clinical product pipeline addressing a wide range of acute and chronic infections in what is today over a $40 billion market, with potential to significantly impact the lives of patients, caregivers and payors worldwide.